Trial Profile
Efficacy of bevacizumab nasal spray for the treatment of epistaxis in Rendu- Osler disease [Efficacité du bevacizumab en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-Osler]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Epistaxis
- Focus Therapeutic Use
- Acronyms ALEGORI
- 12 Dec 2015 Status changed from recruiting to completed, according to European Clinical Trials Database record.
- 06 Jul 2015 New trial record